Royalty Pharma plc Investor Event Transcript, Nov 17, 2026
Royalty Pharma plc (RPRX)
Royalty Pharma reported a third-quarter beat and raise. Last year it looked at 480 opportunities and did about seven deals for $4.7 billion in announced transaction value. Its publicly stated goal is $2 to $2.5 billion a year in capital deployment, and management said those figures will go up over time as big pharma co-funding deals grow. AI summary
Conference Transcript - RPRX 2026-11-17
Speaker 0
Hey, everybody. Thank you so much for joining. Welcome back to the next session at UBS Biopharma Conference in London. So I'm really excited to have Royalty Pharma here, and I have Chris Haidt, who's the Chairman of Partnering and Investments, and Greg Butts, who is EVP of Partnering. So thank you, gentlemen, for joining us. Thank you. Thank you for having us. Yeah, thanks. So kind of very, very unique story and very, you know, well understood by investors, by some investors, I would say. But always good to start with some level of background, just so that people are aware. And if you can just hit a couple of highlights on some of the key takeaways from the third quarter earnings as well, and we can start there.
Chris Hite, Chairman
Sure. Well, thanks again for having us. We really appreciate the opportunity. It's a great conference. So to start with maybe just background on Royalty Pharma, the company's 30 years old. We celebrated our 30th anniversary recently, really created with the idea to buy existing royalty streams from hospitals, foundations, universities way back when, and we still do that. The company went public in 2020, where investment-grade rated capital deployment, publicly stated goals of $2 to $2.5 billion a year. We still buy existing royalty streams. And, but we've really sort of morphed the business and grown the business by co-investing with biotech and pharma to help them fund their R&D programs, provide them capital to launch their drugs, and we call those synthetic royalties. They're not existing royalty streams, but we create new royalties through that process of funding R&D and helping them launch the drugs. The business has grown tremendously. Our opportunity set has grown tremendously. Last year, we looked at 480 opportunities. I think we did about seven deals for about $4.7 billion in announced transaction value. So it's a hugely exciting growth opportunity business. So that's the quick history of the company. Exciting third quarter results. We just announced another beat on the earnings and raise. Some of our exciting products that really delivered on the growth for the quarter were Trimphia, which is J&J's product in IBD. Huge growth in the quarter. Another product called Voronego, which is marketed by Servier. Really strong grower. And then some of our other products that have been consistent growers like Everizdi, another strong quarter. So another great quarter, beat and raise. We're super excited.
Speaker 0
Good. Awesome. So seven out of 480 deals that you looked at, you said? That was in 2025, yes. 480.
Chris Hite, Chairman
Initial reviews.
Speaker 0
Yeah.
Chris Hite, Chairman
Opportunities.
Speaker 0
Right. Okay.
Chris Hite, Chairman
Busy. We were busy and we're busier if that can be possible this year.
Speaker 0
Yeah. Yeah. I guess like it's interesting. More and more sort of this has become a mainstream option or maybe at least like the way that investors look at it, that the growth of royalty space has been spectacular. And so there's been like a secular growth trend that has been happening here. I guess from your vantage point, what do you think has been driving that overall?
Chris Hite, Chairman
So I think it's a lot of factors, I think, that have transformed this opportunity set. One is the financing itself is extraordinarily attractive. So for a biotech company that isn't profitable... You know, they have a couple different options. So let's take the Revolution Medicine deal that we did last year, where we provided Revolution Medicine up to $2 billion in financing to help them advance their pipeline and get ready to launch Dirac's and RASIB. And, you know, a company like that has options to fund itself, right? It was, you know, probably around an $8 billion market cap company. A lot of excitement around the possibility of Dirac and RASA breeding out positively. They could certainly, as most biotech companies do, go to the equity capital markets and fund their pipeline through equity offerings or convertible bond offerings. Or they could partner. You know, they could partner in the U.S. or ex-U.S. That's what most biotech companies do. And that provides capital. The reason why synthetic royalties are very attractive to companies like Revolution Medicine is they can avoid partnering their asset. And when you think about the cost of capital for synthetic royalty versus raising equity capital. It's much more attractive. Think about how that stock has performed since the time of that deal. And when you calculate if they had raised that, the money we gave them in the equity market. And seeing how its stock has performed, you know, that cost of capital far exceeds what they were able to achieve through our deal with them. So, there's a lot of flexibility when you partner with us. We're not, we're a passive partner. We're not active, so we're not asking for JDCs or JSCs. And, obviously, it's not, you know, there's no sort of covenants that restrict your ability to do things. You're not giving away regions to other partners. So, just a lot of attractiveness. So if you're a biotech company that's thinking about raising capital, I think those features have become prevalent in the industry now. I joined Royalty Pharma at the beginning of 2020. Greg just recently joined. But I can tell you, we were both bankers. And, you know, when I left banking in 2019, effectively, we weren't going and pitching synthetic royalties to biotech CFOs. You know, you didn't really do that. You went to the meetings with the capital markets person. You talked about equity and converts. I think now the banking community understands the attractiveness of working with a company like Royalty Pharma for all the reasons I just mentioned. And so it's become part of the ecosystem, of the financing ecosystem. And we did a survey last year with Deloitte, or Deloitte did a survey where they surveyed over 100 biotech CEOs and CFOs. And it really came through through that survey how aware and how willing to use synthetic royalties of finance or companies they are in the industry now. It's really transformed. It's really completely different than it was. Even when I joined the company seven years ago.
Greg Butts, Other
Ash, I'd add one more point, which is, you know, Chris talked about the evolution of what we've done. So monetizing passives, you know, from academic institutions, from universities that. Really was the foundation of royalty pharma at inception. That will continue. Then the creation of the synthetic royalty, which we did, which now has become a very credible option for biotech companies to raise capital as an alternative to equity or convertible debt. And now the third leg of that evolution has been the co-funding deals that we're doing with bigger biotech, big pharma, and that I think will, looking ahead, be an even bigger portion of our kind of growth profile over time. You've seen some, obviously, some recent examples of that. We've done a number of them as well, and we can talk in a minute just around some of the characteristics as to why they're attractive for bigger companies, much in the same way that they. Have been attractive for, you know, smaller relative biotech, like a, like a revolution of medicines.
Speaker 0
Yeah. Yeah, that's great. I guess like I'll ask one question about sort of like small company dynamic and then go to big pharma. When you think about a lot of these biotechs are sometimes in the game of like an M&A exit, right? And for them to have present a holy and uncumbered asset to a big pharma to be acquired.
Greg Butts, Other
Yeah.
Speaker 0
How is that conversation different from versus, let's say, like a royalty-bearing asset? And have you seen anything in that sense that anybody that did a deal with you what still got acquired and wasn't an issue in these type of transactions?
Chris Hite, Chairman
It's a great question. Thank you. Thank you. I would say virtually every product in biopharma has some royalty associated with it, just because when you think about the fragmentation within the discovery of drugs and where they're discovered and how they're discovered and ultimately how they reach the marketplace, there is partnering that happens along the way. And I say that because, you know, large pharma is very... Used to acquiring companies for products that have royalty bearing, that are royalty bearing. It's just part of life. And a lot of the products they get even through not company acquisitions have royalties on them. So pharma is very accustomed to. to that, to that ecosystem of, of buying royalty bearing products. And, and we, we, we provide in any sort of, when that question comes up, and it honestly doesn't come up that often anymore, anymore with a small biotech, you know, they don't really express a concern around a mid single digit royalty that we might achieve through our financing. And there's plenty of examples out there. I was actually on the board of Acceleron. When it was acquired by Merck, and Merck's primary interest there, obviously, was Hutatercept, which has now become a big drug for Merck, that had a royalty of about 22%. And Merck still paid, I think, close to $12 or $13 billion for Acceleron. It's just, you know, and Greg, like myself, I was an M&A advisor for many, many years to large pharma. They're thinking about what's the MPV calculation for the asset, and so the royalty just goes into the calculation of what they're willing to pay. It's not really necessarily a detriment to how they think about, oh, we can't buy this because it has a royalty on it. Got it. Yep.
Greg Butts, Other
And Ash, think of it this way, which is the capital we provide to partners allows them to retain the global rights. So rather than having to do a. A licensing transaction where, you know, you're giving up some economic and operational control that capital then allows the company to hold on to the asset. And again, in the case of Revolution Medicines, you know, then become a global company. And I think that only helps improve the strategic profile of a company, even if there's, you know, some small royalty that's embedded in the company.
Speaker 0
Great.
Chris Hite, Chairman
Awesome.
Speaker 0
So yeah, talking about big pharma partnership, and you've done a lot of these, right? I guess one of the questions that I get from investors, particularly journalist investors, is why does pharma need to get into these type of transactions? Because they have pristine balance sheets. So if you can talk about that conceptually, and there is a lot of pattern cliff coming up for big pharma companies over the next five years. Do you think that that would sort of accelerate those type of deals for you?
Chris Hite, Chairman
Yeah, so I think, you know, large pharma looking to external partners to help them fund their R&D is, you know, it's accelerating, the opportunity set. It's large, and it's accelerating. And the reason why I think it's accelerating is a couplefold. One, the... There was a change in accounting under US GAAP, FASB and US GAAP, you know, clearly now allow contra-R&D accounting. So what does that mean? That means that the deal, a deal that we do with a large pharmaceutical company, you know, for a half a billion dollars, say, that allows them to spend a half a billion dollars more on pipeline. And maintain the same level of EPS. What head of R&D at Large Pharma wouldn't want to spend another half a billion dollars on their pipeline? Everyone wants to. And I think what you've seen is you've seen companies like J&J do a deal with us and Pfizer and Merck and Biogen and Teva. Sanofi and some really high-quality companies do these transactions, and I think what it's causing is a lot of other pharmaceutical companies to stand up or sit up and say, wow, these companies are actually gaining an advantage by expanding their spend level without necessarily changing their R&D expense by utilizing external. They're financing sources to do that, and it creates an advantage for them. So it's almost sort of feeding upon itself. People see that, and they say, you know, we really need to investigate this. And the other thing that's, I think, very attractive for large pharma is it allows them to risk share on an asset that with a partner that's not going to be... We're demanding, once again, to be an active partner. We are passive in these investments. We're not sitting on JDCs. We're not sitting on JSCs. So we're an attractive partner because we're passive. That's risk sharing with them and allows them to do more on their R&D budget. So really super attractive modality for them. And I think it's just really the beginning.
Greg Butts, Other
Yeah. Ash, think of it this way, which is the opportunity sets the... Products that are in pharma or big biotech's R&D portfolio today, but it's also the assets that enter their portfolio through business development. And again, I think so many companies you asked about, you know, the patent cliffs. Investors want sustainable revenue growth. You do that through investment in your R&D efforts, whether it's internal or external. For us, it's highlighting that this is an applicable financing tool for all assets in the portfolio, whether they're homegrown or they come in through the outside, which, as you know, is a very common tool now for big companies to advance their R&D portfolio.
Speaker 0
Yeah. How do you, like in that setup, how do you, you know, avoid negative selection bias? Like if pharma wants to partner out some of their lower priority pipeline programs with you, then how do you sort of weed that out?
Chris Hite, Chairman
It's a great question and something we're very focused on. We do... It's hard to describe how active the dialogue is across Pharma, but it is very active, and some of that is involving us outbound to them, saying, hey, we'd love to fund XYZ program. Some of it is inbound, and with them saying, hey, would you like to fund XYZ? Um, it's a constant dialogue. We've made it very clear to pharma that we want to fund their highest priority programs, uh, that we don't want that negative selection bias. We don't want to be funding things that wouldn't be funded except for our funding. Right. So that's a key thing that we, that we do all the time. You know, it goes back to the core of what royalty pharma is, and Our core really is having extraordinarily, we have to be extraordinarily disciplined in any investment that we're doing. We have to do good deals. That is the bottom line for us on everything we're doing. We look at everything as a really tough grader. Uh, and it's our highest priority to keep the bar very high and be very disciplined on all of our investments. And so there's a lot that we look at that we decide not to do. Um, but it's, you're right to raise the question because that's the natural inclination is to, to be skeptical and say, aren't they going to get stuff that they wouldn't be funding except for your funding? But that's always sort of the pushback that we, and they, they understand that by the way. Okay, perfect.
Speaker 0
Maybe just talking about some of the R&D co-funding deals, like if they continue, I mean, this momentum has been particularly strong. What would that mean for your capital deployment goals longer term?
Greg Butts, Other
Yeah, I think it only continues to go up. And again, going back to the point I made before, which is the funding opportunity are both the... Programs in their portfolio today, as well as ones that come in from the outside via business development or M&A activity. Um, and, you know, we've got the scale from a, from a financial resource perspective to, um, undertake, you know, large, large, you know, multi hundred million dollar billion plus, you know, uh, dollar type investments that are commensurate with, as Chris said, funding the best programs, you know, the programs that are the highest. Priority, the biggest growth drivers for those companies. So again, as we look at capital deployment that we've talked about with you, those numbers will go up over time, much as the overall R&D budgets for big pharma, big biotech continue to grow. And I think that trend will only continue. New and again. You know, we also, I think, could probably characterize that from the standpoint of the capitaliment figures in the context of China. I'm sure a question you'll ask about, and, you know, that is an opportunity that is still relatively nascent, both in terms of that read and understanding the use of royalty monetizations for, you know, what is primarily a universe of passive royalties that have been created through all the business development activity over the last number of years, you know, with Western multinationals licensing assets from from from China innovators. And, and then those assets maturing in the hands of big, big pharma through phase two, through phase three. So, you know, we view China as in addition to our state of capital deployment goals.
Speaker 0
Okay, perfect. And then if I see just some of the recent deals that you've done, there is a few examples where you've done the deal with the same manufacturer. Just trying to understand how the conversation goes there. Like, is there a framework that allows you to do multiple deals with the same company, like existing relationship that you've dealt with them, talk to them, or how they run their R&D program? So, like, for example, you've done a few deals with Teva recently, which I cover. So is there a framework that there could be some partner of choice that would start to emerge as you're going through this process?
Chris Hite, Chairman
It's a great question. I think, you know, we have done a number of repeat business type deals. I think it's trying to be a good partner. You mentioned Teva, where we funded their long-acting injectable olanzapine program, which has obviously just gotten recently approved, so we're very excited about that and that launch. And then we signed a deal earlier this year for their IL-15 with indications in vitiligo and celiac. Super excited about that opportunity as well. You know, we're very impressed with the management team there. I think Richard's done an amazing job. We really like the team. I think it's like anything. It's human nature. When you sort of develop a relationship and you build trust, it's easier to go back to that person that you've enjoyed working with. So I think that's just, you know, human nature. I do think that, you know, We have constant active dialogue with a lot of parties that we haven't done deals with, and it's just, once again, it's an asset selection. But I think, to your point around repeat business, it's, yeah, like cytokinetics, we did many deals with cytokinetics as an example. It's really just, I think, just being a good partner.
Speaker 0
That's great. Okay. And then another way to look at it, you know, just kind of the division between the public and the private side, like, do you think that there would be more deals with private entities? A lot of the private companies are in early stage of development, which you're starting to do some deals there. But do you think that overall, does this sort of as a percentage of the overall pie grow from here?
Chris Hite, Chairman
I can take that.
Greg Butts, Other
I mean, I think, first off, we don't have a kind of a philosophical view of only partnering with private or public companies. You know, I think our view is partnering with companies that have the best assets, where we also then can generate attractive returns for our shareholders. That set of characteristics may sit within a public company. It may sit within a private company. I think... From an industry characteristic standpoint, more mature company or assets, excuse me, typically sit within public companies than they do private companies. Not always, but again, if you were just to look across the distribution of biopharma, the more mature post-proof-of-concept assets sit within. We want to make sure our partner has the adequate capital structure and availability of capital to successfully develop and commercialize products. The public markets typically provide that level of capital depth and capital availability, but again, we start first with the product and is it a great product, and then ask the questions around, is this also a great partner? That we think on a passive basis, again, to Chris's point, you know, we're investing in teams and companies that can develop those drugs. Do we think they then have the right resources, capital resources, organization resources to be successful?
Chris Hite, Chairman
A great, great example of that is, you know, a private company that has one of our fastest growing. Royalty Streams is Servier, right, with Voronigo. That launch has been, you know, very, very strong. But to Greg's point, we don't have a philosophical view, but it is really about asset selection and high bar, and typically private companies are just earlier stage nature. So we really want to see something that has proof of concept data. Got it.
Speaker 0
Okay. I mean, one of the remarkable things that I've seen, just the consistency of your IRR, really unparalleled by anybody, right? What is the secret sauce that drives that, like, what extent of due diligence that you do that I'm sure, like, a lot of people are not able to replicate and build a model like this?
Chris Hite, Chairman
Yeah, I think it's a track record we're super proud of, and it goes back many, many years of consistent returns that are really attractive, unlevered IRRs, and I think it boils back to, I hate to sound repetitive, but asset selection and having a high bar. We have an incredible investment team of investment professionals that... Are really good at what they do. They're very diligent. You know, we've brought in lots of capabilities since I've been at the company almost seven years now around real world evidence and claims data analysis. And now we've started really sort of utilizing artificial intelligence in our examination of the data that we're able to pull. And combining all these resources, I think we're really able to think very thoughtfully around what a target product profile may look like, or how does this TPP compare to others in the marketplace, and really build out a commercial forecast that oftentimes is different than consensus. And through that... Modeling and forecasting, you know, we're able to achieve these really outstanding returns, but it really, it builds back to our internal team and the process that we, it's a rigorous process and a very high bar, and I think that over 30 years of sort of just. Doing things has really led to that capability.
Greg Butts, Other
Ash, I'd add one other point, and that is just the long duration of our investment time horizon. So Chris mentioned that we've been doing this for three decades, but I think that patient mindset of not... Feeling, um, forced to deploy capital or make an investment if, you know, the fact pattern doesn't support a great product and a great set of investment returns. Um, you know, we obviously think about our capital deployment, um, um, in a way that benefits our shareholders, but also looking at over the timeframe of, of, uh, of, of royalties and, um, making sure that when we do invest, it's because we've studied it. A space, a product, a team for a long time and then have conviction. And there may be categories and products that we follow for multiple years before we feel as though that level of conviction that we need to have to justify the returns is achieved. And so I think that that kind of patient approach to investing is what allows the bar to remain. It's incredibly high and reproducible, which is something, as Chris said, we're very proud of.
Chris Hite, Chairman
Yeah, that's wonderful.
Speaker 0
Maybe just one final question. I know China is a big topic, but just from your vantage point, do you think that it has been more of an opportunity set for you or a potential threat? The way that you think about getting assets, let's say, within U.S., how much do you delve into due diligence and what might emerge from the competitive side from China, let's say?
Chris Hite, Chairman
Yeah, I think, you know, we hired the head of Morgan Stanley's health care practice in Asia this year. His name is Ken Sun, to lead our effort in China, and You know, we've all seen a number of, you know, just the explosion of growth of the out-licensing that has occurred from China to Western multinational companies, and many times those Chinese companies have negotiated very attractive royalty streams should those products get approved. We are tracking. At all the large pharmaceutical companies, those products as they advance through development stages, and we're ensuring that, you know, we're communicating to the Chinese companies in China, you know, of our interest. You know, I think we did a deal last year that caught people's attention when we acquired from B1, which obviously had its origin in China, and a lot of people recognize it in China as, you know, as a Chinese, historically a Chinese company. But when we bought the royalty stream that they had on Amgen's and Deltra for about $900 million, that really caught the attention of the Chinese innovators that have been doing a lot of the out-licensing. So I think that sets the stage for us to... Be in a very good position to seize upon those royalty opportunities, but once again, we have to really sort of track the development of those products at the Western multinationals. And when the time is right, you know, I'm sure there's going to be a nice, very nice opportunity set there.
Speaker 0
Yeah, great. Awesome. Well, thank you so much for all this. Very helpful discussion. And with that, we can wrap it up.
Chris Hite, Chairman
Thank you so much.
Speaker 0
I appreciate it.